Livanova Stock News

LivaNova (LIVN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates

LivaNova (LIVN) delivered earnings and revenue surprises of 12.50% and 4.12%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

LivaNova provides high-tech medical devices for the benefit of healthcare professionals, patients, and healthcare systems around the world. Considering the geographic diversification of the business m

LONDON--( BUSINESS WIRE )--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its fourth-quarter and full-year 2022 results

LivaNova PLC (NASDAQ:LIVN ) Q3 2022 Results Earnings Conference Call November 2, 2022 8:00 AM ET Company Participants Matthew Dodds - Senior Vice President, Corporate Development Damien McDonald - Chi

LivaNova (LIVN) delivered earnings and revenue surprises of 1.75% and 2.46%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

LivaNova is clearly doing better in weaker segments and technical profitability has actually been reached now on an operating level. Neuromodulation has been seeing slowing unit growth as seen by sign

LivaNova PLC (NASDAQ:LIVN ) Q2 2022 Earnings Conference Call August 3, 2022 8:00 AM ET Company Participants Matthew Dodds - SVP, Corporate Development Damien McDonald - CEO & Director Alex Shvartsburg

LivaNova (LIVN) delivered earnings and revenue surprises of 3.92% and 2.61%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

LivaNova PLC (NASDAQ:LIVN ) Q1 2022 Results Earnings Conference Call May 4, 2022 8:00 AM ET Company Participants Matthew Dodds - Senior Vice President, Corporate Development Damien McDonald - Chief Ex

Within the last quarter, LivaNova (NASDAQ:LIVN) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 0 0 0 Last 30D 0

LivaNova (LIVN) delivered earnings and revenue surprises of -7.69% and 3.09%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

LivaNova (LIVN) delivered earnings and revenue surprises of -7.69% and 3.09%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Upgrades According to Morgan Stanley, the prior rating for Royalty Pharma PLC (NASDAQ:RPRX) was changed from Equal-Weight to Overweight. In the fourth quarter, Royalty Pharma showed an EPS of $0.80, c

New York, USA, March 14, 2022 (GLOBE NEWSWIRE) -- Vagus Nerve Stimulators Market is Expected to Witness Positive Growth With A CAGR of 9.06% During the Study Period (2018-26) As per DelveInsight analysis, the Vagus Nerve Stimulators Market is witnessing a surge primarily due to the rising prevalence of neurological diseases, the increasing popularity of VNS therapy as an alternative or even conjunctive treatment in cases where drug resistance develops, growing research in studying the effects of VNS on other indications, technological advancements leading to the development of new products such as non-invasive Vagus Nerve Stimulation devices, and others. DelveInsight''s Vagus Nerve Stimulators Market Insights report provides the current and forecast market, upcoming device innovation, individual leading companies market shares, challenges, market drivers, barriers, and trends, and key Vagus Nerve Stimulators companies in the market. Key Takeaways from the Global Vagus Nerve Stimulators Market According to DelveInsight analysis, North America is anticipated to dominate the global Vagus Nerve Stimulators market during the forecast period.